PTAFR, platelet activating factor receptor, 5724

N. diseases: 96; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0002792
Disease: anaphylaxis
anaphylaxis 		0.010 Biomarker phenotype BEFREE Use of PAF-R antagonists during AS could reduce epinephrine-related complications and improve the treatment of epinephrine refractory cases. 31755606 2020
CUI: C0004623
Disease: Bacterial Infections
Bacterial Infections 		0.010 Biomarker group BEFREE Here, we review the evidence for the roles of local tissue hypoxia-induced inflammation, HIF-1α and PAFR in facilitating bacterial infections in COPD. 31663668 2020
CUI: C0009319
Disease: Colitis
Colitis 		0.010 Biomarker disease BEFREE Platelet activating factor receptor regulates colitis-induced pulmonary inflammation through the NLRP3 inflammasome. 30976089 2019
CUI: C0012739
Disease: Disseminated Intravascular Coagulation
Disseminated Intravascular Coagulation 		0.010 Biomarker disease BEFREE The PAF-R antagonist WEB-2086 protected mice against PAF-induced death by reducing DIC and oxidative stress. 31442556 2019
CUI: C0021390
Disease: Inflammatory Bowel Diseases
Inflammatory Bowel Diseases 		0.010 Biomarker group BEFREE We investigated the role of PAFR in pulmonary EIMs of IBD, using dextran sulfate sodium (DSS) and anti-CD40 murine models of colitis. 30976089 2019
CUI: C0276447
Disease: Rhinovirus infection
Rhinovirus infection 		0.010 AlteredExpression disease BEFREE Pre-treatment of A549 respiratory epithelial cells with a physiological concentration (10<sup>-7</sup>M) of 25(OH)D induced transient resistance to infection with RV-16 and attenuated RV-16-induced expression of the genes encoding intercellular adhesion molecule 1 (ICAM-1, a cell surface glycoprotein that acts as the cellular receptor for major group rhinoviruses) and platelet-activating factor receptor (PAFR, a G-protein coupled receptor implicated in adhesion of Streptococcus pneumoniae to respiratory epithelial cells). 30476590 2019
CUI: C0002736
Disease: Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis 		0.010 Biomarker disease BEFREE A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment. 29472887 2018
CUI: C0007114
Disease: Malignant neoplasm of skin
Malignant neoplasm of skin 		0.010 Biomarker disease BEFREE PAF-R agonists have been shown to modulate tumorigenesis and/or tumor growth in various skin cancer models by suppressing either cutaneous inflammation and/or anti-tumoral adaptive immunity. 30314274 2018
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.010 AlteredExpression disease BEFREE Cervical cancer-derived cell lines (C33, SiHa, and HeLa) and squamous carcinoma cell lines (SCC90 and SCC78) express higher levels of PAFR mRNA and protein than immortalized keratinocytes. 29459885 2018
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases 		0.010 Biomarker group BEFREE PAFR is considered an important drug target for treating asthma, inflammation and cardiovascular diseases. 29808000 2018
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 AlteredExpression disease BEFREE mRNA expression of platelet activating factor receptor (PAFR) in peripheral blood mononuclear cells is associated with albuminuria and vascular dysfunction in patients with type 2 diabetes. 29247656 2018
CUI: C0027962
Disease: Melanocytic nevus
Melanocytic nevus 		0.010 Biomarker disease BEFREE To further dissect the contextual role of PAF-R agonism on tumorigenesis, we chronically administered systemic PAF-R agonist, carbamoyl-PAF (CPAF) to mice under a cutaneous chemical carcinogenesis protocol, recently characterized to initiate both NMSC and melanocytic nevus formation that can progress to malignant melanoma. 30314274 2018
CUI: C0028945
Disease: oligodendroglioma
oligodendroglioma 		0.010 Biomarker disease BEFREE CAP1, HBXIP, KLK6, PARK7, PTAFR) might counteract oligodendroglioma development. 29890994 2018
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.010 Biomarker disease BEFREE Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells. 30577630 2018
CUI: C0279070
Disease: Adult Oligodendroglioma
Adult Oligodendroglioma 		0.010 Biomarker disease BEFREE CAP1, HBXIP, KLK6, PARK7, PTAFR) might counteract oligodendroglioma development. 29890994 2018
CUI: C0280475
Disease: Childhood Oligodendroglioma
Childhood Oligodendroglioma 		0.010 Biomarker disease BEFREE CAP1, HBXIP, KLK6, PARK7, PTAFR) might counteract oligodendroglioma development. 29890994 2018
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.010 Biomarker disease BEFREE Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells. 30577630 2018
CUI: C0596321
Disease: Chemical Carcinogenesis
Chemical Carcinogenesis 		0.010 Biomarker phenotype BEFREE To further dissect the contextual role of PAF-R agonism on tumorigenesis, we chronically administered systemic PAF-R agonist, carbamoyl-PAF (CPAF) to mice under a cutaneous chemical carcinogenesis protocol, recently characterized to initiate both NMSC and melanocytic nevus formation that can progress to malignant melanoma. 30314274 2018
CUI: C0699893
Disease: Skin carcinoma
Skin carcinoma 		0.010 Biomarker disease BEFREE To further dissect the contextual role of PAF-R agonism on tumorigenesis, we chronically administered systemic PAF-R agonist, carbamoyl-PAF (CPAF) to mice under a cutaneous chemical carcinogenesis protocol, recently characterized to initiate both NMSC and melanocytic nevus formation that can progress to malignant melanoma. 30314274 2018
CUI: C0751396
Disease: Well Differentiated Oligodendroglioma
Well Differentiated Oligodendroglioma 		0.010 Biomarker disease BEFREE CAP1, HBXIP, KLK6, PARK7, PTAFR) might counteract oligodendroglioma development. 29890994 2018
CUI: C1096293
Disease: Macroangiopathy
Macroangiopathy 		0.010 AlteredExpression disease BEFREE PAFR overexpression in PBMCs may link diabetic nephropathy to macroangiopathy through impairment of endothelial function in patients with T2DM. 29247656 2018
CUI: C1456781
Disease: Benign melanocytic nevus
Benign melanocytic nevus 		0.010 Biomarker disease BEFREE To further dissect the contextual role of PAF-R agonism on tumorigenesis, we chronically administered systemic PAF-R agonist, carbamoyl-PAF (CPAF) to mice under a cutaneous chemical carcinogenesis protocol, recently characterized to initiate both NMSC and melanocytic nevus formation that can progress to malignant melanoma. 30314274 2018
CUI: C1519689
Disease: Tumor Promotion
Tumor Promotion 		0.010 Biomarker phenotype BEFREE These results indicate that the context of PAF-R agonist exposure via either chronic cutaneous or systemic administration, result in seemingly disparate effects on tumor promotion. 30314274 2018
CUI: C4048329
Disease: Immunosuppression
Immunosuppression 		0.010 Biomarker disease BEFREE Platelet-activating factor-receptor (PAF-R) agonists are pleiotropic lipid factors that influence multiple biological processes, including the induction and resolution of inflammation as well as immunosuppression. 30314274 2018
CUI: C0005750
Disease: Blind Loop Syndrome
Blind Loop Syndrome 		0.010 GeneticVariation disease BEFREE Association of platelet-activating factor receptor gene rs5938 (G/T) and rs313152 (T/C) polymorphisms with coronary heart disease and blood stasis syndrome in a Chinese Han population. 28197937 2017